Qualitative live-cell molecular test for methicillin-resistant Staphylococcus aureus (MRSA) - powered by innovative Smarticles technology
A new way to stay ahead of MRSA
The cobas® vivoDx MRSA provides rapid phenotypic detection of methicillin-resistant staphylococcus aureus (MRSA) colonization using the cobas® vivoDx System. MRSA infections represent a tremendous burden on the healthcare system and are associated with significant healthcare costs. As the first of a new class of molecular diagnostics based on the novel Smarticles technology, the cobas® vivoDx MRSA assay offers a new way to tackle MRSA in hospital infection prevention programs.
Explore a novel, high-performing and efficient method for MRSA screening
Innovative technology – Speed and simplicity of molecular diagnostics with phenotypic detection
Easy workflow – Direct from sample with <1 minute pre-analytical workflow per sample
Fast phenotypic result – ~5 hour turnaround time for timely infection control decisions
Confidence in results – direct detection, not limited by mechanisms of resistance
Through the combination of the innovative Smarticles technology and the automated cobas® vivoDx System, cobas® vivoDx MRSA offers an advanced option for MRSA detection.
Smarticles technology combines the speed and simplicity of molecular diagnostics with phenotypic detection to deliver rapid results. It requires minimal preparation and provides results in hours instead of days as compared to traditional growth-based identification and susceptibility test methods.
Learn more about Smarticles technology.